No annual revenue total was found in MIRA Pharmaceuticals, Inc.'s SEC filings.
MIRA Pharmaceuticals, Inc. (MIRA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-9.48M
-22.1% vs year-ago TTM
Operating cash flow (TTM)
$-4.64M
+23.7% vs year-ago TTM
Free cash flow
—
EPS
$-1.35
-164.7% vs prior year
Dividend per share
None
Shares outstanding
42.02M
+149.9% vs prior year
Net cash
$4.60M
FY 2023
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MIRA (Nasdaq)
- Incorporated in
- FL
- Headquarters
- Miami, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1904286
- Former names
- Mira1a Therapeutics, Inc. (until May 2, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Net income | -$10.4M | -$7.9M | -$12.0M |
| Diluted EPS | -$1.35 | -$0.51 | -$0.85 |
| Operating cash flow | -$4.7M | -$5.6M | -$4.5M |
| Total assets | $11.1M | $2.9M | $4.9M |
| Total liabilities | $702,068 | $723,349 | $558,097 |
| Stockholders' equity | $10.4M | $2.2M | $4.4M |
| Cash and investments | $11.0M | $2.8M | $4.6M |
| Total debt | — | — | $5,061 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 17, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 16, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 1, 2026 | Sep 1, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
All 198 MIRA Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.